Dr. Wouter Hendrickx is an investigator in the immunology, Inflammation and metabolism department and member of the Cancer Precision Medicine Working Group at Sidra Medicine. He is the PI of the Functional Cancer Omics lab and has experience in stem cell and cancer research at the universities of Brussels (VUB), Leuven (KUL) and Norwich (UEA). Where he gained an MSc in biomedical Science (2004) and an MSc Bio-informatics (2005) and a PhD in Medical Science respectively (2012). He has worked on several different projects relating to the tumor micro environment including extensive work on the role of MMP’s and the degradome. He has experience with classic molecular biology techniques as well as advanced 3D cell culture and proteomics technology. At Sidra he has focused since 2014 on the tumor immune micro environment deploying bio-informatic tools to analyze gene-expression data form bulk tumor for immune related signatures and other determinants of the immune phenotype and translating the findings to the wet lab environment. He was a participant of the EU FP6 and PF7 grant framework and is a 2015 QNRF JSREP awardee. Since 2019 he leads Sidra Medicine’s efforts in establishing a Biorepository for Pediatric cancer Patients.
We investigate the immunogenetic profile of colon cancer patients as Part of a JSREP funded grant. This is the first study of its kind in Qatar that enabled us to establish a Next Generation Sequencing (NGS) cancer cohort locally. This project involves RNA sequencing, whole exome sequencing as well as T cell receptor profiling of 360 colon cancer patients. The sequencing is conducted by the Sidra Genomics core facility and the bioinformatics pipeline was developed with collaboration from the Bioinformatics division. Immune phenotyping and the determination of genetic determinants of these phenotypes is performed in line with our previous research using the TCGA breast and colon cancer cohorts. The output of this new colon cancer immune genetic project will not only expand our current understanding of the tumor immune environment but will also provide us some insight on its role in the diagnosis, prognosis and treatment of cancer patients. The technological developments in this project will pave the way for NGS-based cancer research and treatment in Qatar. The project also supports education, training and capacity building in Qatar and involves an international PhD student from LUMC. This project will serve as the foundation in our efforts to bring NGS capabilities to our pediatric cancer research.In addition, we are involved in several international collaborations focusing on the therapeutic manipulation of the tumor immune microenvironment and the genomic determinations of these interventions. Following up on the genetic profiling of cancer samples, our wet lab research extends to functional omics to unravel the mechanistic basis of the NGS findings. For this purpose, we employ various methodologies, including 3D in vitro modeling and single cell analyses.
Jessica Roelands PhD CandidateAffiliated with LUMC (Netherlands)Email: jroelands (@) sidra.org ORCID: 0000-0003-3631-2041Publons: https://publons.com/researcher/1519038/jessica-roelands/Apryl SanchezResearch AssistantEmail: asanchez (@) sidra.org
SELECTED PUBLICATIONS(†equal contribution, *corresponding):
- Roelands J, Hendrickx W, Kuppen P, Mall R, Zoppoli G, Saad M, Halliwill K, Curigliano G, Rinchai D, Decock J, Delogu LG, Turan T, Samayoa J, Chouchane L, Wang E, Finetti P, Bertucci F, Miller LD, Galon J, Marincola FM, Ceccarelli M, Bedognetti D*. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune respons. J Immunother Cancer (2019, to appear)
- Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis L, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola M, Bedognetti D†*, Adams S†*. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod.Sci Rep(2019)9(1):8572.
- Bertucci B, Finetti P, Simeone I, Hendrickx W, Wang E, Marincola F, Viens P, Mamessier E, Ceccarelli M, Birnbaum D, Bedognetti D. The Immunologic Constant of Rejection classification (ICR) refines the prognostic value of conventional prognostic signatures in breast cancer. Br J Cancer (2018) 19(11):1383-1391.
- Orecchioni M, Bedognetti D, Newman L, Fuoco C, Spada F, Hendrickx W,Marincola FM,Sgarrella F,Rodrigues FA, Ménard-Moyon C,Cesareni G,Kostarelos K,Bianco, Delogu LG. Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene nanomaterials on human immune cells. Nat Commun (2017)8(1): 1109.
- HendrickxW, Simeone I, AnjumS, MokrabY, Bertucci F, Finetti P, CuriglianoG, SeligerB, CeruloL, Tomei S, DeloguLG, MaccalliC, WangE, MillerLD, MarincolaFM, CeccarelliM†, BedognettiD*†. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology (2017)6(2):e1253654.
- Roelands J, Decock J, Boughorbel S, Rinchai D, Maccalli C, Ceccarelli M, Black M, Print C, Chou J, Presnell S, Quinn C, Jithesh P, Syed N, Al Bader S, Wang E, Marincola FM, Chaussabel D, Kuppen P, Miller L†, Bedognetti D†*, Hendrickx W†. A collection of annotated and harmonized human breast cancer gene expression datasets including immunologic classification.F1000Research (2017)6:296.
- Maccalli C, Giannarelli D, Chiarucci C, Cutaia C, Giacobini G, Hendricx W, Amato G, Annesi D, Bedognetti D, Altomonte M, Danieli R, Calabro’ L, Di Giacomo AM, Marincola FM, Parmiani G, Maio M. Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. OncoImmunol (2017) 6:e1323618.